![David A. Baker](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profiel
David A.
Baker is the founder who founded Promentis Pharmaceuticals, Inc. in 2007 and held the title of Director.
He received a doctorate degree from Arizona State University in 1999 and an undergraduate degree from Montana State University in 1992.
Eerdere bekende functies van David A. Baker
Bedrijven | Functie | Einde |
---|---|---|
Promentis Pharmaceuticals, Inc.
![]() Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | Oprichter | - |
Opleiding van David A. Baker
Arizona State University | Doctorate Degree |
Montana State University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Promentis Pharmaceuticals, Inc.
![]() Promentis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Promentis Pharmaceuticals, Inc. engages in the develop of novel compounds for the treatment of schizophrenia and other central nervous system disorders. The firm's drug development efforts are focused on the neurotransmitter glutamate and its critical role in the pathophysiology of schizophrenia and other disesses. It discovers, develops and markets new drugs for the treatment of important human diseases, focusing initially on developing a new antipsychotic drug to treat schizophrenia. The company was founded by David A. Baker and John Mantsch in 2007 and is headquartered in Milwaukee, WI. | Health Technology |